HTSC

First‑half 2026 China securities firms report a 13.4% earnings jump driven by AI‑powered trading, higher‑margin wealth‑management, and easing CSRC rules – why top brokers thrive and investors should focus on tech and diversification.

China’s 2026 innovation‑drug sector sees a shift from high‑investment to profit‑oriented growth, with rising sales, selective profit surges, record BD deals, and robust R&D spending—an insight into the next wave of Chinese biotech success.

HTSC reports a 49% revenue jump to 31.3B RMB and 54% profit rise, yet shares rise only 0.5%. See how the firm’s growth, margin gains and geopolitical risks shape its future.

HTSC’s latest earnings reveal a profitable pivot into high‑margin AI, automotive, and industrial components, with disciplined cost control, expanded R&D, and a resilient supply chain driving 7% gross‑margin growth and attracting institutional in…